CPRX - Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28 2024 | Benzinga
CORAL GABLES, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its fourth quarter and full-year 2023 financial results after the market close on February 28, 2024.
Catalyst's management team will host a conference call and webcast the following morning, Thursday, February 29, 2024, at 8:30 AM ET, to discuss the Company's financial results and provide a business update.
| Conference Call & Webcast Details |
| Date: |
| February 29, 2024 |
| Time: |
| 8:30 AM ET |
| US/Canada Dial-in Number: |
| (877) 407-8912 |
| International Dial-in Number: |
| (201) 689-8059 |
A webcast and accompanying materials will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on the Catalyst website for 30 days following the date of the event.
About Catalyst Pharmaceuticals
With exceptional patient ...